Previous 10 | Next 10 |
ANN ARBOR, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at the Jefferies London Healthcare Conference on Wednesday, November 16 th , 2022. A live audio webcast can be accessed on the investors...
Esperion Therapeutics, Inc. (ESPR) Q3 2022 Earnings Conference Call November 1, 2022 08:00 ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - President & Chief Executive Officer JoAnne Foody - Chief Medical...
Esperion Therapeutics press release ( NASDAQ: ESPR ): Q3 GAAP EPS of -$0.81 beats by $0.12 . Revenue of $19M (+31.9% Y/Y) misses by $0.68M . “During the third quarter of 2022 our team has remained focused on closing out our unprecedented CLEAR Outcomes t...
– CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion – – Remain On Track to Report Topline Results in January 2023, with Full Results Targeted to be Presented in March at the American College of Cardiology 72 ...
Esperion Therapeutics ( NASDAQ: ESPR ) is scheduled to announce Q3 earnings results on Tuesday, November 1st, before market open. The consensus EPS Estimate is -$0.93 (+64.5% Y/Y) and the consensus Revenue Estimate is $19.68M (+36.6% Y/Y). Over the last 1 year, ESPR ...
– Overview of its investigational pipeline, planned scientific focus, and future growth drivers – – Wednesday, November 9 th @ 10amET – ANN ARBOR, Mich., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today...
ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, November 1 st , 2022. Following the release, company management will host a web...
ANN ARBOR, Mich., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at Morgan Stanley’s 20 th Annual Global Healthcare Conference and also participate in H.C. Wainwright’s Annual Global Investment...
Esperion Therapeutics reported its Q2 earnings that revealed a beat on revenue, but a miss on EPS. However, the company announced that it has hit 100% MACE-4 accumulation. The company’s mixed earnings were only a slight improvement over Q1. I was expecting the market to punish ...
Following earning-led gains in the previous session, Esperion Therapeutics ( NASDAQ: ESPR ), a pharma company focused on high cholesterol levels, dropped Wednesday after Credit Suisse downgraded the stock to Underperform from Neutral, noting a limited upside until a key data r...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...